Shares of Mylan N.V. (MYL) were slammed in trading on Tuesday due to a lawsuit alleging the company of conspiring to fix generic drug prices. The company’s president, Rajiv Malik, was named in the lawsuit. This marks a strong development in the ongoing probe into prescription drug pricing that should yield more volatility to the sector as time proceeds. MYL shares settled down -6.62% to close at 35.11 for the session. Keep an eye on the stock as this story is still developing.